1132. Package # 7.1 (Female oncology screening)

The Women's Oncopanel is a complex of 5 tumor markers that helps assess the risk of developing common cancers in women: breast, ovarian, thyroid, pancreatic, and gastrointestinal. It is recommended for those with a family history of cancer and for post-treatment monitoring.

The package includes the following markers:

• CA 15-3 – a breast cancer marker;
• CA 125 – a sensitive marker for ovarian tumors, especially epithelial ones;
• CA 19-9 – a marker for tumors of the pancreas, gallbladder, stomach, and intestines;
• CEA – a nonspecific marker whose levels may be elevated in tumors of the gastrointestinal tract, lungs, and breast;
• Thyroglobulin – a protein used as a tumor marker in patients with thyroid cancer (especially papillary and follicular forms).

Tumor markers are not a stand-alone diagnostic method, so their results should be interpreted in conjunction with clinical, laboratory, and instrumental data. Elevated levels are also possible in inflammatory, hyperplastic, or benign processes.

• women with a strong family history of cancer;
• if a tumor is suspected (based on ultrasound, MRI, or CT scan results);
• in the presence of non-specific complaints (weight loss, anemia, abdominal pain, etc.);
• as part of a follow-up examination after cancer treatment (to monitor for recurrence or metastases);
• as part of preventive cancer screening after age 40, especially for hormone-dependent diseases or menopause.

• Venous blood

In order to exclude factors that may affect the test results, we recommend to follow the preparation rules: